A Comprehensive 4-layered In Silico Pharmacogenomics Analysis of the Genetic Addiction Risk Severity (GARS) Test: Strong Genetic Evidence Supporting GARS as a Novel Personalized Pre-addiction Assessment Tool in the Opioid Crisis Era

This paper provides scientific evidence for the importance of incorporating GARS as a predictive test to identify Pre-addiction, introduce unique therapeutic targets assisting in the treatment of pain, drug dosing of prescription pharmaceuticals, and identify the risk for subsequent addiction early in -life.

Authors

Institutions

Publication Details

Journal
Current Pharmaceutical Biotechnology
Published
2025-04-18
DOI
https://doi.org/10.2174/0113892010353450250408114725
Primary Topic
Attention Deficit Hyperactivity Disorder
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Comprehensive 4-layered In Silico Pharmacogenomics Analysis of the Genetic Addiction Risk Severity (GARS) Test: Strong Genetic Evidence Supporting GARS as a Novel Personalized Pre-addiction Assessment Tool in the Opioid Crisis Era

Panayotis K. Thanos, Rossano Kepler Alvim Fiorelli, Foojan Zeine, Edward J. Modestino et al.
Current Pharmaceutical Biotechnology
Attention Deficit Hyperactivity Disorder
article

A Comprehensive 4-layered In Silico Pharmacogenomics Analysis of the Genetic Addiction Risk Severity (GARS) Test: Strong Genetic Evidence Supporting GARS as a Novel Personalized Pre-addiction Assessment Tool in the Opioid Crisis Era

Panayotis K. Thanos, Rossano Kepler Alvim Fiorelli, Foojan Zeine, Edward J. Modestino, Eliot L. Gardner, Colin Hanna, David Baron, Jag Khalsa, Jean Lud Cadet, Marjorie C. Gondré‐Lewis, Daniel Sipple, Nicole Jafari, Abdalla Bowirrat, Igor Elman, Albert Pinhasov, Keerthy Sunder, Milan Makale, Catherine A. Dennen, Mark S. Gold, Kai-Uwe Lewandrowski, Kevin T. Murphy, Eric R. Braverman, Kenneth Blum, Rajendra D. Badgaiyan, EraAlireza Sharafshah
article en

Abstract

This paper provides scientific evidence for the importance of incorporating GARS as a predictive test to identify Pre-addiction, introduce unique therapeutic targets assisting in the treatment of pain, drug dosing of prescription pharmaceuticals, and identify the risk for subsequent addiction early in -life.

Current Pharmaceutical BiotechnologyVol. 26(13)
University of California, Riverside (US), Cambridge Health Alliance (US), National Institutes of Health (US), National Institute on Drug Abuse (US), Harvard University (US), Guilan University of Medical Sciences (IR), Washington University in St. Louis (US), Thomas Jefferson University Hospital (US), UC San Diego Health System (US), University of California San Diego (US), Hospital Universitário Gaffrée e Guinle (BR), Minneapolis Business College (US), Northeast Health (US), University School (US), Michigan Head and Spine Institute (US), Fundación Universitaria Sanitas (CO), Curry College (US), Ariel University (IL), Case Western Reserve University (US), California State University, Long Beach (US), Universidade Federal do Estado do Rio de Janeiro (BR), The Chicago School (US), Western University of Health Sciences (US)
Good health and well-being
Openalex Percentile: Top 90%
Attention Deficit Hyperactivity Disorder
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.